Halozyme Therapeutics (HALO)
NASDAQ:HALO
Want to see HALO full AI Analyst Report?
Total Valuation
Halozyme has a market cap or net worth of $8.18B. The enterprise value is $8.08B.
Market Cap$8.18B
Enterprise Value$8.08B
Share Statistics
Halozyme has 118,613,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding118,613,000
Owned by Insiders1.20%
Owned by Institutions27.59%
Financial Efficiency
Halozyme’s return on equity (ROE) is 6.49 and return on invested capital (ROIC) is 23.59%.
Return on Equity (ROE)6.49
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)23.59%
Return on Capital Employed (ROCE)0.35
Revenue Per Employee3.99M
Profits Per Employee905.40K
Employee Count350
Asset Turnover0.55
Inventory Turnover1.73
Valuation Ratios
The current PE Ratio of Halozyme is 12.7. Halozyme’s PEG ratio is -1.04.
PE Ratio12.7
PS Ratio5.77
PB Ratio165.22
Price to Fair Value165.22
Price to FCF12.51
Price to Operating Cash Flow12.03
PEG Ratio-1.04
Income Statement
In the last 12 months, Halozyme had revenue of 1.40B and earned 316.89M in profits. Earnings per share was 2.64.
Revenue1.40B
Gross Profit1.09B
Operating Income816.29M
Pretax Income466.88M
Net Income316.89M
EBITDA904.34M
Earnings Per Share (EPS)2.64
Cash Flow
In the last 12 months, operating cash flow was 677.41M and capital expenditures -9.76M, giving a free cash flow of 667.65M billion.
Operating Cash Flow677.41M
Free Cash Flow667.65M
Free Cash Flow per Share5.63
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change27.91%
50-Day Moving Average65.62
200-Day Moving Average69.05
Relative Strength Index (RSI)56.79
Average Volume (3m)1.61M
Important Dates
Halozyme upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Halozyme as a current ratio of 4.66, with Debt / Equity ratio of 95.04%
Current Ratio4.66
Quick Ratio3.66
Debt to Market Cap0.00
Net Debt to EBITDA-0.15
Interest Coverage Ratio45.03
Taxes
In the past 12 months, Halozyme has paid 149.99M in taxes.
Income Tax149.99M
Effective Tax Rate0.32
Enterprise Valuation
Halozyme EV to EBITDA ratio is 8.77, with an EV/FCF ratio of 12.30.
EV to Sales5.68
EV to EBITDA8.77
EV to Free Cash Flow12.30
EV to Operating Cash Flow12.17
Balance Sheet
Halozyme has $318.62M in cash and marketable securities with $2.14B in debt, giving a net cash position of -$1.83B billion.
Cash & Marketable Securities$318.62M
Total Debt$2.14B
Net Cash-$1.83B
Net Cash Per Share-$15.39
Tangible Book Value Per Share-$12.63
Margins
Gross margin is 76.93%, with operating margin of 58.45%, and net profit margin of 22.69%.
Gross Margin76.93%
Operating Margin58.45%
Pretax Margin33.43%
Net Profit Margin22.69%
EBITDA Margin64.75%
EBIT Margin58.45%
Analyst Forecast
The average price target for Halozyme is $84.48, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$84.48
Price Target Upside21.93% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast39.12%
EPS Growth Forecast-24.20%